AbbVie Inc. Files 8-K on Financials and Debt

Ticker: ABBV · Form: 8-K · Filed: 2025-10-03T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, debt-maturity, 8-k

TL;DR

AbbVie dropped an 8-K on Oct 3rd covering financials and a bunch of senior notes due dates.

AI Summary

On October 3, 2025, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior notes due in 2027, 2028, 2029, and 2031, indicating ongoing financial activities and potential debt management strategies.

Why It Matters

This filing provides insight into AbbVie's current financial standing and its approach to managing its debt obligations, which can impact investor confidence and future strategic decisions.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting financial condition and does not indicate any immediate or significant negative events.

Key Numbers

2027 — Senior Notes Due (Indicates a debt maturity date)
2028 — Senior Notes Due (Indicates a debt maturity date)
2029 — Senior Notes Due (Indicates a debt maturity date)
2031 — Senior Notes Due (Indicates a debt maturity date)

Key Players & Entities

AbbVie Inc. (company) — Registrant
October 3, 2025 (date) — Date of earliest event reported
0001551152-25-000043 (filing_id) — Accession Number
Delaware (state) — State of Incorporation
1 NORTH WAUKEGAN ROAD (address) — Business Address
NORTH CHICAGO (city) — Business Address City
IL (state) — Business Address State
60064 (zip_code) — Business Address Zip
320375147 (ein) — Employer Identification Number

FAQ

What specific financial information is being reported in this 8-K?

This 8-K report is filed under 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', indicating it contains updates on the company's financial performance and related documentation.

What are the maturity dates of the senior notes mentioned in the filing?

The filing references senior notes due in 2027, 2028, 2029, and 2031.

What is the filing date of this 8-K report?

The report was filed on October 3, 2025.

What is AbbVie Inc.'s state of incorporation?

AbbVie Inc. is incorporated in Delaware.

What is the primary business of AbbVie Inc. according to the filing?

AbbVie Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001551152-25-000043.txt : 20251003 0001551152-25-000043.hdr.sgml : 20251003 20251003160903 ACCESSION NUMBER: 0001551152-25-000043 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20251003 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251003 DATE AS OF CHANGE: 20251003 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 251373843 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20251003.htm 8-K abbv-20251003 0001551152 false 0001551152 2025-10-03 2025-10-03 0001551152 us-gaap:CommonStockMember exch:XNYS 2025-10-03 2025-10-03 0001551152 us-gaap:CommonStockMember exch:XCHI 2025-10-03 2025-10-03 0001551152 abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2025-10-03 2025-10-03 0001551152 abbv:Sec2.125SeniorNotesdue2028Member exch:XNYS 2025-10-03 2025-10-03 0001551152 abbv:Sec2625SeniorNotesDue2028Member exch:XNYS 2025-10-03 2025-10-03 0001551152 abbv:Sec2125SeniorNotesDue2029Member exch:XNYS 2025-10-03 2025-10-03 0001551152 abbv:Sec1.250SeniorNotesdue2031Member exch:XNYS 2025-10-03 2025-10-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  _____________________________________________________ FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 3, 2025   ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware   001-35565   32-0375147 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)  _____________________________________________________ 1 North Waukegan Road North Chicago ,  Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐                       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027 ABBV27 New York Stock Exchange 2.125% Senior Notes due 2028 ABBV28 New York Stock Exchange 2.625% Senior Notes due 2028 ABBV